Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: A global developer, manufacturer, and marketer of specialized scientific instruments used to accelerate drug discovery research. The company targets bottlenecks in drug discovery, including ADMET screening, molecular biology, genomics, proteomics, and high-throughput screening. Operations span the U.S., U.K., Germany, Austria, Belgium, and sales facilities in Japan, France, and Canada.
Key Financial Metrics (Year Ended Dec 31, 2002)
| Metric | 2002 | 2001 |
|---|---|---|
| Total Revenues | $57.4 million | $40.9 million |
| Net Income | $0.7 million | $(5.2) million |
| Operating Income | $1.6 million | $(4.7) million |
| Cost of Product Revenues | $28.8 million (50.2% of rev) | $20.2 million (49.5% of rev) |
| Research & Development | $4.1 million | $3.2 million |
| Cash and Cash Equivalents | $15.3 million | $29.4 million |
| Working Capital | $31.8 million | $32.6 million |
| Long-Term Debt | $0.4 million | $0.6 million |
| Stockholders' Equity | $88.4 million | $66.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 40% ($16.5 million) compared to 2001. Approximately 68% of this increase was attributed to the base revenues of acquisitions made in 2002 and the full-year impact of 2001 acquisitions.
- Profitability Turnaround: The company returned to profitability with a net income of $0.7 million, reversing a net loss of $5.2 million in 2001. This was driven by revenue growth and the elimination of non-cash warrant interest expense that impacted prior years.
- Acquisition Activity: Significant acquisitions included Genomic Solutions (Oct 2002), Walden Precision Apparatus (July 2002), and Asys Hitech (Dec 2001). These drove increases in R&D, Sales & Marketing, and G&A expenses.
- Foreign Currency Impact: A weaker U.S. dollar in 2002 resulted in a foreign currency gain of $0.4 million, compared to a loss of $0.1 million in 2001. Approximately 59% of revenues were derived from non-U.S. operations.
- Stock Compensation: Stock compensation expense decreased to $1.3 million in 2002 from $2.7 million in 2001.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management anticipates continued significant development expenditures and a balanced portfolio strategy of internal R&D and acquisitions. The company expects available cash and debt capacity to be sufficient for operations for at least 12 months. No specific quantitative revenue guidance was provided for 2003.
Key Risks:
- Integration Risk: Significant risk associated with integrating Genomic Solutions, which has a history of losses and an accumulated deficit of $72.0 million as of June 2002.
- Customer Concentration: Amersham Biosciences accounted for 18% of 2002 revenues (down from 30% in 2001). Termination of this distribution agreement could materially impact the business.
- Intellectual Property: Risks related to patent infringement claims and the ability to protect proprietary technologies in a rapidly changing market.
- Market Conditions: Dependence on pharmaceutical and biotechnology R&D spending, which is subject to economic downturns and capital market conditions.
Legal Contingencies:
- Harvard University: Trademark dispute settled in Dec 2002 via a royalty-free license agreement.
- Paul D. Grindle: Arbitration regarding 1996 purchase price adjustments. Arbitrator ruled in favor of Harvard Bioscience in Oct 2002; Grindle is seeking to vacate the decision in Superior Court.
- Affymetrix: Genomic Solutions subsidiary is involved in litigation regarding license fees. A $1.45 million counter-claim by Affymetrix is fully reserved in financial statements.
- Oxford Gene Technology: Patent infringement suit filed against Genomic Solutions subsidiary in Dec 2002; management intends to vigorously defend.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Genomic Solutions and whether it is achieving projected synergies given its history of losses.
- Amersham Biosciences Relationship: Monitor the status of the distribution agreement with Amersham Biosciences, which represents a significant portion of international revenue.
- Cash Burn Rate: Assess the sustainability of the $15.3 million cash balance given the company's aggressive acquisition strategy and ongoing R&D spend.
- Legal Resolution: Track the status of the Grindle arbitration appeal and the Affymetrix/Oxford Gene Technology litigation to ensure no unexpected liabilities arise.
- Goodwill Valuation: Review the $31.1 million goodwill balance (29% of total assets) for potential impairment risks under SFAS 142.